BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF

摘要

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

主权项

1. An isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 comprising an antibody VL, wherein the VL comprises the amino acid sequence:[FW1]SGSLSNIGRNX1VN[FW2]LX2NX3RX4X5[FW3]ATWDDSX6X7GWX8[FW4] wherein [FW1], [FW2], [FW3] and [FW4] represent VL framework regions, and wherein X1 represents amino acid residues Proline (P), Glutamic Acid (E) or Aspartic Acid (D); X2 represents amino acid residues Asparagine (N) or Aspartic Acid (D); X3 represents amino acid residues Glutamine (Q) or Leucine (L); X4 represents amino acid residues Leucine (L) or Proline (P); X5 represents amino acid residues Glycine (G) or Serine (S); X6 represents amino acid residues Leucine (L) or Histidine (H); X7 represents amino acid residues Lysine (K), Proline (P), Isoleucine (I) or Asparagine (N); and, X8 represents amino acid residues Leucine (L) or Threonine (T).